Linked Life Data

6793256

Source:http://linkedlifedata.com/resource/pubmed/id/6793256

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1981-12-21
pubmed:abstractText
Hexamethylmelamine (NSC-13875) was given to 15 patients with disseminated prostatic cancer in a daily x 21 schedule at 6-week intervals. The schedule was 320 mg/m2/day in four divided doses for good-risk patients and 240 mg/m2/day for poor-risk patients. No response was observed in 14 evaluable patients, but seven patients had stable disease. Limiting toxicity was nausea and vomiting which developed in 80% of the patients and it was the reason for discontinuation of therapy in one patient. Hematologic toxicity was acceptable, and occurred in 80% of the patients. Leukopenia was more frequent than thrombocytopenia, occurring in 80% and 20%, respectively. All patients had been previously treated with hormones, but 6/15 were never exposed to cytotoxic chemotherapy.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0190-1206
pubmed:author
pubmed:issnType
Print
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
309-12
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1981
pubmed:articleTitle
Phase II study of hexamethylmelamine for disseminated prostatic carcinoma.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.